anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rhododendri Mollis Flos (R. mole Flos), the dried flowers of Rhododendron mole G. Don, have the ability to relieve pain, dispel wind and dampness, and dissolve blood stasis, but they are highly poisonous. The significance of this study is to explore the analgesic application potential of R. mole Flos and its representative component. According to the selected processing methods recorded in ancient literature, the analgesic activities of wine- and vinegar-processed R. mole Flos, as well as the raw product, were evaluated in a writhing test with acetic acid and a formalin-induced pain test. Subsequently, the HPLC-TOP-MS technique was utilized to investigate the changes in active components before and after processing once the variations in activities were confirmed. Based on the results, rhodojaponin VI (RJ-Vl) was chosen for further study. After processing, especially in vinegar, R. mole Flos did not only maintain the anti-nociception but also showed reduced toxicity, and the chemical composition corresponding to these effects also changed significantly. Further investigation of its representative components revealed that RJ-VI has considerable anti-nociceptive activity, particularly in inflammatory pain (0.3 mg/kg) and peripheral neuropathic pain (0.6 mg/kg). Its toxicity was about three times lower than that of rhodojaponin III, which is another representative component of R. mole Flos. Additionally, RJ-VI mildly inhibits several subtypes of voltage-gated sodium channels (IC50 > 200 μM) that are associated with pain or cardiotoxicity. In conclusion, the chemical substances and biological effects of R. mole Flos changed significantly before and after processing, and the representative component RJ-VI has the potential to be developed into an effective analgesic.
<P>PROBLEM TO BE SOLVED: To provide a new class compound which is an interleukin-1β converting enzyme inhibitor.  <P>SOLUTION: An ICE (interleukin-1β converting enzyme) inhibitor characterized by a specific structure and pharmacological characteristics is provided. A pharmaceutical composition containing the compound is also provided. The compound and the pharmaceutical composition are sufficiently suitable for inhibiting the ICE activity, and as a result, can advantageously be used as medicines for interleukin-1-mediated diseases (including inflammatory diseases, autoimmune diseases and nerve denaturating diseases). A method for inhibiting ICE activities and a method for treating interleukin-1-mediated diseases using the compound and the composition are also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Chronic Granulomatous Disease (CGD) is an inherited immune disorder involving decreased phagocytic superoxide oxygen radical production, resulting in increased susceptibility to infections. Furthermore, there is a predominance of immune-related inflammatory problems in a subset of CGD patients, such as the inflammatory bowel disease (CGD-IBD). CGD-IBD is often complicated by obstruction, strictures, fissures, fistulae, and extra-intestinal problems. In fact, it is clinically and histologically indistinguishable from Crohn's Disease (CD), another inflammatory bowel disease that affects the general population. Crohn's disease (CD) is a prototypic T helper cell type 1 (Th1) immune disease. Since CGD-IBD bears such close resemblance to CD, it is possible that CGD-IBD is also immune-based. Furthermore, mice studies also support a primarily immune basis for CGD-IBD. However, currently there is little data on this Crohn's-like CGD-IBD in human patients. Treatment for the Crohn's-like CGD-IBD has been primarily oral or topical corticosteroids. Antibiotics have been ineffective and stool cultures typically do not identify clear pathogens. Many patients with the Crohn's-like CGD-IBD disease remain steroid-dependent, thus new therapeutic regimens are needed.

This is a Phase I/II study that will evaluate the safety and efficacy of Tumor Necrosis Factor Alpha Inhibitor (Infliximab or Adalimumab) in CGD patients with symptomatic Crohn's-like IBD. Infliximab and Adalimumab are standard-of-care treatments for moderate to severe CD, with extensive experience using these agents being well documented in terms of safety and efficacy. Preliminary reports from ongoing studies of CD at NIH are encouraging in inducing remission. We will also evaluate changes in immunophenotype and cytokine profiles of peripheral blood and colonic lamina propria lymphocytes following treatment. In addition, we will evaluate the immunophenotype and cytokine profile of blood and mucosal cells in CGD patients, with or without IBD, to determine the CGD-specific cytokine profile. Specific cytokine profiles have been observed in different genetic immunodeficiencies, despite similar IBD clinical manifestation.

Documentation of clinical status will be performed using the Crohn's Disease Activity Index (CDAI). Potential effects of genetic variation (including CGD mutation type) on the expression of IBD in patients with CGD, and their responses to treatment will also be assessed. The long-term goal of this study is to establish better or alternative treatment modalities with low risk profiles for CGD patients with Crohn's-like IBD.
BACKGROUND: Studies on the early retinal changes in Diabetic Retinopathy (DR) have demonstrated that neurodegeneration precedes vascular abnormalities like microaneurysms or intraretinal hemorrhages. Therefore, there is a growing field of study to analyze the cellular and molecular pathways involved to allow for the development of novel therapeutics to prevent the onset or delay the progression of DR. Molecular Mechanisms: Oxidative stress and mitochondrial dysfunction contribute to neurodegeneration through pathways involving polyol, hexosamine, advanced glycation end products, and protein kinase C. Potential interventions targeting these pathways include aldose reductase inhibitors and protein kinase C inhibitors. Neurotrophic factor imbalances, notably brain-derived neurotrophic factor and nerve growth factor, also play a role in early neurodegeneration, and supplementation of these neurotrophic factors show promise in mitigating neurodegeneration. Cellular Mechanisms: Major cellular mechanisms of neurodegeneration include caspase-mediated apoptosis, glial cell reactivity, and glutamate excitotoxicity. Therefore, inhibitors of these pathways are potential therapeutic avenues. Vascular Component: The nitric oxide pathway, critical for neurovascular coupling, is disrupted in DR due to increased reactive oxygen species. Vascular Endothelial Growth Factor (VEGF), a long-known angiogenic factor, has demonstrated both damaging and neuroprotective effects, prompting a careful consideration of long-term anti-VEGF therapy.
CONCLUSION: Current DR treatments primarily address vascular symptoms but fall short of preventing or halting the disease. Insights into the mechanisms of retinal neurodegeneration in the setting of diabetes mellitus not only enhance our understanding of DR but also pave the way for future therapeutic interventions aimed at preventing disease progression and preserving vision.
In the MAD stage, participants will receive subcutaneous injection of TB001 once daily for 7 days, planning to ascend from 60 μg，150ug to 300 μg or higher dose (whether to proceed to the next higher cohort based on dose escalation criteria). Actual dose of TB001 may vary based on safety, tolerability and PK data from previous cohorts.
Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of therapy. (See WARNINGS).

Because of the hepatotoxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically.

Periodic (every 6 months) x-ray examinations of bone age should be made during treatment of children to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.

Androgenic anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. Therefore, caution is required when administering these agents to patients with a history of cardiovascular disease or who are at risk for cardiovascular disease. Serum determination of lipid levels should be performed periodically and therapy adjusted accordingly.

Hemoglobin and hematocrit should be checked periodically for polycythemia in patients who are receiving high doses of anabolic steroids.
Spectral analysis of heart rate variability (HRV) is a widely used, noninvasive technique to assess autonomic indexes of neural cardiac control. The presence of low-frequency (LF) and high-frequency (HF) oscillatory rhythms in the variability of the R-R interval (RRI) is well established. To date, it is believed that LF is mediated by the parasympathetic and sympathetic systems, whereas HF is mediated primarily by the parasympathetic system. The current study used HRV in order to characterize autonomic nerve system (ANS) activity in patients before and during stable hypnosis, nociceptive surgical stimulation and (adequate) or light (inadequate) analgesia. These effects may vary with the anesthetic technique used. Despite these previous studies, attempts to derive the relation between anesthetic concentrations and HRV have so far remained inconclusive. Such characterization would provide additional information on the behavior of the ANS during different anesthesic drug level and may lay the basis for the development of new clinical application.

Propofol is now widely used in clinical practice because of its favorable recovery profile and low incidence of side effects. However, induction of anesthesia with propofol is often associated with a significant decrease in arterial blood pressure and heart rate (HR). The hypotensive effect of propofol has been attributed to a decrease in systemic vascular resistance or in cardiac output caused by a combination of venous and arterial vasodilation, impaired baroreflex mechanisms and depression of myocardial contractility. Besides, there are some conflicting data regarding the effects of propofol on cardiac sympathetic or parasympathetic tone.

The investigators hypothesis was that at different propofol anesthetic drug level would have reproducible effects on HRV. In addition, these results should be reliably characterized in anesthetized patients provided that HRV uses analysis that can assess transient and rapid changes in ANS activity. Therefore, the first goal of this study was to test the hypothesis that propofol anesthesia would affect HRV depending on the concentrations, and so do opioid and midazolam. Second, the investigators will evaluate the effect of anesthetic combination of autonomic system.
PROBLEM TO BE SOLVED: To obtain the subject preventive and treating agent controlling prevention or progress without inducing adverse effect even performing peroral digestion for a long period of time by including chlorella or chlorella extract as an active component. SOLUTION: This agent contains chlorella of family of green algae, belonging to genus chlorella, e.g. chlorella regularis, chlorella vulugaris or chlorella pyrenoidosa and/or a chlorella extract prepared by an extraction operation using an extracting solution of e.g. an organic solvent such as acetone or methanol as an active component. When the preventive and treating agent is administrated, its dose is preferably daily 3-8 g (dry weight). An additive amount of the chlorella to a food, preferably usual 20-50 wt.% of tablet is used.
Coronary artery reblockage remains still a drawback of percutaneous coronary interventions even in the era of drug-eluting stents (DES). DESs working principle consists of the delivery of controlled amounts of antiproliferative agents at the local level, which results in the suppression of neontimal proliferation, the main cause of lumen re-narrowing after stent implantation.At present, several DES platforms have been developed and evaluated for clinical use. They differ between them with regard to the stent type, anti-proliferative drug, presence of polymers employed for drug storage and modification of drug-release kinetics as well as type of polymer used for this purpose. Most of the DES platforms have used agents from the "limus family". Although the majority of DESs employ polymer coating to control drug storage and release, in view of the increasing safety and efficacy associated with the long-term presence of polymers a strong interest has recently been shown in the development DES platforms that do not require permanent polymers. Trials as ACTION or JUPITER II have demonstrated that not all DESs are associated with the expected improved outcomes. On the other hand, not all successful DESs have been equally effective in the reduction of restenosis. Thus, rapamycin-eluting stents (Cypher stents) have been associated with lower angiographic and clinical restenosis rates than paclitaxel-eluting stents (Taxus stents). Similarly, Cypher stents have been superior to Endeavor stents regarding the primary end point of late luminal loss in the recent ENDEAVOR III trial. Meanwhile, the on-site rapamycin-coated stents (ISAR stents) had an equivalent antiproliferative efficacy to Taxus stents in the ISAR-TEST trial. However, none of these studies evaluated angiographic restenosis as their primary endpoint and no direct comparisons between the 3 DES -Cypher, Endeavor and ISAR stents, have been performed. The Cypher stent is a stainless steel stent coated with sirolimus with use of permanent polymers while the Endeavor stent is a cobalt alloy based stent coated with zotarolimus which also uses permanent polymers for drug-storage and release. The ISAR stent is a rough surface stainless steel stent that can be coated with sirolimus in the cath lab without requiring permanent polymeric coating.
Participants will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for 6 weeks. Alongside supplementation, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched control consisting of flexibility training (low-intensity exercise) for 6 weeks.
Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.
Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
Healthy controls are ≥18 years old, no previous history of SARS-CoV-2 infection, and no previous history of autoimmune diseases. All the HC group were injected with 2 or 3 doses of inactivated SARS-CoV-2 vaccines.
The E. coli BR56(KCTC 0056BP) contg. 56kDa antigen of Rickettsia tsutsugamushi Boryeong is prepd.. The 56kDa protein antigen of Rickettsia tsutsugamushi Boryeong is obtd. by: purifying DNA of R. tsutsugamushi cultured in mouse L-cell; cutting the purified DNA with restriction enzyme; searching gene library obtd. from lambda GB11 pharge vector DNA with patient's serum. The obtd. 56kDa protein antigen is useful for the prodn. diagnostic reagent and vaccine.
A system and method for patient healthcare information management. The system includes a fingerprint scanner that generates fingerprint data by scanning the finger of a patient. That fingerprint data is forwarded to a hand scan server that performs a lookup to retrieve a corresponding patient ID or social security number. That patient ID or social security number is then sent to a healthcare server, such as at a hospital or other healthcare facility, to retrieve the healthcare information for the patient. That is particularly useful for patients who are unconscious or otherwise unable to recall or relay their identifying information and/or healthcare information history to the healthcare practitioner. In addition, the system can include an imaging capture device to take a picture of the patient. That image is displayed in conjunction with annotations that indicate the patient healthcare information history for the patient. That enables the healthcare practitioner to rapidly and easily see the patient's healthcare history and related details.
Healthcare-associated infection control practices in Japan were not commonly acknowledged until mid-1980s, when an academic society focusing on infection control was founded and large academic hospitals began to establish infection control departments. In the late 1990s, the society established a nationwide surveillance system mainly focusing on surgical site infection (SSI). Coincidentally, the guideline for the prevention of SSI published by the US Centers for Disease Control and Prevention (CDC) was revised in 1999. It was translated into Japanese, and has been widely referenced in Japanese clinical practices. Since then, both epidemiological research and preventive practices in Japan have been developed. Overall SSI incidence was about 10% in the early 2000s, but fell to 7% by 2007, with a further reduction to 5% in 2020. A large SSI database cohort created through surveillance enabled us to conduct research regarding risk factors for SSI following various types of surgery. In mid-2010s, the revision of CDC's SSI prevention guideline and the new one by the World Health Organization were published. Novel evidence-based SSI prevention practices such as normal body temperature and antiseptic-impregnated sutures are recommended, and have been timely introduced into Japanese surgical practice. However, many of the practices and devices shown to be effective in preventing SSI are not approved for reimbursement by public healthcare insurance in Japan, which has so far prevented those measures from being widely used in Japanese healthcare.
Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
The intervention will focus on identifying risk factors for depression and anxiety and will quantitate the educational component of the POWER Obesity group intervention delivered by mental health professionals that are currently presenting for 30 min during the Monday session to address the root causes of obesity as well as to encourage positive lifestyle changes (e.g. sleep, diet, sun exposure, circadian rhythms, and addictions). The previously published hypothesis identifies triggers, that combined, could cause mental health problems. The 10 groups of triggers are: (1) Genetic, (2) Developmental, (3) Lifestyle, (4) Circadian Rhythm, (5) Addiction, (6) Nutrition, (7) Toxic, (8) Social/Complicated Grief, (9) Medical Condition, and (10) Frontal Lobe. Each of these factors will be dealt with in the lifestyle intervention.
Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte- selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non- protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA. Specific delivery agents are provided. Methods for in vivo, in vitro and ex vivo leukocyte-selective delivery using the delivery agents are also disclosed.
This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
PURPOSE: A composition containing ginseng extract for preventing and treating type 2 diabetes is provided to reduce blood glucose and to improve insulin resistance. CONSTITUTION: A pharmaceutical composition for preventing and treating type 2 diabetes contains ginseng extract as an active ingredient. The ginseng extract contains 0.2-10 weight% of ginsenoside Re, Rg1, Rg2, Rb1, Rb2, or Rd ingredient. The ginseng extract is isolated using ethyl alcohol, butyl alcohol, and distilled water. The ginseng extract is from flowers of Panax ginseng, Panax quinquefolium, Panax notoginseng, Panax japonicum, and Panax vietnamensis. The composition is used in the form of tablet, powder, granule, capsule, suspension, emulsion, or suppository.